Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CD123+ Acute Myeloid Leukemia”

63 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 63 results

Large-scale testing (Phase 3)Study completedNCT02472145
What this trial is testing

An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

Who this might be right for
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC 326
Early research (Phase 1)Active Not RecruitingNCT05233618
What this trial is testing

Study of Tagraxofusp for Post-Transplant Maintenance for Patients With CD 123+ AML, MDS, MF and CMML (HSCT 002)

Who this might be right for
MyelofibrosisChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Karen Ballen, MD 44
Testing effectiveness (Phase 2)Active Not RecruitingNCT06456463
What this trial is testing

Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy

Who this might be right for
Acute Myeloid Leukemia
Stemline Therapeutics, Inc. 85
Testing effectiveness (Phase 2)Ended earlyNCT02152956
What this trial is testing

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Who this might be right for
AML
MacroGenics 244
Very early researchActive Not RecruitingNCT06765876
What this trial is testing

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Who this might be right for
Leukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic 18
Testing effectiveness (Phase 2)Ended earlyNCT02992860
What this trial is testing

Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY

Who this might be right for
Myelodysplastic Syndrome (MDS)Acute Myeloid Leukemia (AML)
GWT-TUD GmbH 25
Very early researchEnded earlyNCT02623582
What this trial is testing

CD123 Redirected Autologous T Cells for AML

Who this might be right for
Relapsed or Refractory Acute Myeloid Leukemia
University of Pennsylvania 7
Testing effectiveness (Phase 2)Study completedNCT06006403
What this trial is testing

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Relapse Leukemia+1 more
Chongqing Precision Biotech Co., Ltd 5
Early research (Phase 1)Ended earlyNCT03203369
What this trial is testing

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cellectis S.A. 1
Testing effectiveness (Phase 2)Looking for participantsNCT06420063
What this trial is testing

Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

Who this might be right for
AMLAcute Myeloid LeukemiaAML, Adult Recurrent+1 more
Essen Biotech 85
Early research (Phase 1)Looking for participantsNCT04318678
What this trial is testing

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Who this might be right for
AML/MDSB-ALLT-ALL+1 more
St. Jude Children's Research Hospital 108
Early research (Phase 1)Looking for participantsNCT06835140
What this trial is testing

CD123-CD16-NK Cells Immunotherapy for AML

Who this might be right for
AML (Acute Myelogenous Leukemia)NK CellCD123+ Acute Myeloid Leukemia
Chunji Gao 9
Early research (Phase 1)Ended earlyNCT03672851
What this trial is testing

Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

Who this might be right for
Acute LeukemiaAcute Leukemia in RelapseAcute Myeloid Leukemia+1 more
Second Affiliated Hospital of Xi'an Jiaotong University 2
Early research (Phase 1)Active Not RecruitingNCT05362773
What this trial is testing

MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Leukemia, Acute MyeloidMyelodysplastic SyndromesClassical Hodgkin Lymphoma+5 more
MacroGenics 130
Early research (Phase 1)WithdrawnNCT05513612
What this trial is testing

Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

Who this might be right for
Acute Myeloid Leukemia (AML)B-cell Non-Hodgkin's Lymphoma (B-NHL)Multiple Myeloma (MM)+2 more
Shanghai Pudong Hospital
Early research (Phase 1)Looking for participantsNCT06690827
What this trial is testing

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN

Who this might be right for
AML (Acute Myeloid Leukemia)BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd 30
Early research (Phase 1)Active Not RecruitingNCT06359002
What this trial is testing

Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Who this might be right for
Relapsed / Refractory AMLRelapsed / Refractory MDS
Byondis B.V. 16
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Very early researchUnknownNCT05574608
What this trial is testing

Allogenic CD123-CAR-NK Cells in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia RefractoryAcute Myeloid Leukemia Recurrent
Affiliated Hospital to Academy of Military Medical Sciences 12
Early research (Phase 1)Looking for participantsNCT06034275
What this trial is testing

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome
Vincerx Pharma, Inc. 36
Next Page